Stacy M Plum

Summary

Affiliation: EntreMed Inc
Country: USA

Publications

  1. ncbi Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development
    S M Plum
    EntreMed, Inc, 9640 Medical Center Drive, Rockville, MD 20850, USA
    Vaccine 19:1294-303. 2000
  2. ncbi Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model
    Stacy M Plum
    EntreMed, Inc, Rockville, Maryland 20850, USA
    Clin Cancer Res 9:4619-26. 2003
  3. ncbi Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction
    Stacy M Plum
    EntreMed, Inc, Rockville, Maryland 20850, USA
    Immunopharmacol Immunotoxicol 26:29-41. 2004
  4. ncbi Anti-angiogenic vaccines as a treatment modality for cancer
    Stacy M Plum
    EntreMed Inc, 9640 Medical Center Drive, Rockville, MD 20850, USA
    Curr Opin Investig Drugs 5:1243-6. 2004
  5. ncbi Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis
    Stacy M Plum
    EntreMed, Inc, Rockville, MD 20850, USA
    BMC Musculoskelet Disord 10:46. 2009
  6. ncbi Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity
    Todd A Hembrough
    EntreMed, Inc, 9640 Medical Center Dr, Rockville, MD 20850, USA
    Blood 103:3374-80. 2004

Collaborators

  • Li Zhang
  • Todd A Hembrough
  • Bonnie M Swerdlow
  • Glenn M Swartz
  • Jose F Ruiz
  • Hans J Hammers
  • Mark S Williams
  • Victor S Pribluda
  • Dudley K Strickland

Detail Information

Publications6

  1. ncbi Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development
    S M Plum
    EntreMed, Inc, 9640 Medical Center Drive, Rockville, MD 20850, USA
    Vaccine 19:1294-303. 2000
    ..These data suggest that a heparin binding domain peptide of FGF-2, when presented to a host in a liposomal adjuvant formulation, can ultimately lead to inhibition of angiogenesis and tumor growth...
  2. ncbi Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model
    Stacy M Plum
    EntreMed, Inc, Rockville, Maryland 20850, USA
    Clin Cancer Res 9:4619-26. 2003
    ..In this study, we determine the antitumor effect of rhEndostatin administered alone or in combination with Adriamycin against established orthotopic murine mammary carcinoma...
  3. ncbi Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction
    Stacy M Plum
    EntreMed, Inc, Rockville, Maryland 20850, USA
    Immunopharmacol Immunotoxicol 26:29-41. 2004
    ..Thus, while vaccination against FGF-2 induces a specific FGF-2 antibody response, and inhibits angiogenesis and tumor development in a pathological setting, it does not adversely alter normal physiological events dependent on FGF-2...
  4. ncbi Anti-angiogenic vaccines as a treatment modality for cancer
    Stacy M Plum
    EntreMed Inc, 9640 Medical Center Drive, Rockville, MD 20850, USA
    Curr Opin Investig Drugs 5:1243-6. 2004
    ..In this review we describe a number of novel vaccines that target mediators of angiogenesis and inhibit tumor progression in preclinical models...
  5. ncbi Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis
    Stacy M Plum
    EntreMed, Inc, Rockville, MD 20850, USA
    BMC Musculoskelet Disord 10:46. 2009
    ..We investigated the impact of orally administered 2ME2 on the initiation and development of proliferative synovitis using the anti-collagen monoclonal antibodies (CAIA) model...
  6. ncbi Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity
    Todd A Hembrough
    EntreMed, Inc, 9640 Medical Center Dr, Rockville, MD 20850, USA
    Blood 103:3374-80. 2004
    ....